KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer.
MedComm (2020)
; 5(5): e545, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38721007
ABSTRACT
The first-line therapy pattern transition of metastatic HER2-positive gastric cancer is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD-L1 CPS≥1. In the future, the first-line therapy pattern of metastatic HER2-positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
MedComm (2020)
Año:
2024
Tipo del documento:
Article